5984. Diversity in the Pulmonary Embolism Response Team Model: An Organizational Survey of the National PERT Consortium Members.
作者: Geoffrey D Barnes.;Christopher Kabrhel.;D Mark Courtney.;Soophia Naydenov.;Todd Wood.;Rachel Rosovsky.;Kenneth Rosenfield.;Jay Giri.; .
来源: Chest. 2016年150卷6期1414-1417页 5992. Introducing High-Sensitivity Cardiac Troponin T as a Biomarker of OSA-Related Cardiovascular Morbidity in Obesity Hypoventilation Syndrome.
作者: Denis Monneret.;Philippe Giral.;Dominique Bonnefont-Rousselot.;Frederic Roche.
来源: Chest. 2016年150卷6期1408-1409页 5997. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
作者: Peter A Noseworthy.;Xiaoxi Yao.;Neena S Abraham.;Lindsey R Sangaralingham.;Robert D McBane.;Nilay D Shah.
来源: Chest. 2016年150卷6期1302-1312页
The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has been a major advance for stroke prevention in atrial fibrillation (AF). Patients and clinicians now have a choice between different NOACs, but there is no direct comparative effectiveness evidence to guide decision-making. We aimed to compare the effectiveness and safety of dabigatran, rivaroxaban, and apixaban in clinical practice.
|